| Q1  2026 |
| ≡ |
John Rogers - Ariel Investments |
Add 8.26% |
1,034,950 |
0.17 |
| ≡ |
Mason Hawkins - Southeastern Asset Management |
Add 49.49% |
4,241,829 |
3.03 |
| Q4  2025 |
| ≡ |
Mason Hawkins - Southeastern Asset Management |
Add 5.01% |
409,032 |
0.36 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 33.11% |
695,081 |
0.53 |
| Q3  2025 |
| ≡ |
Mason Hawkins - Southeastern Asset Management |
Add 13.03% |
941,031 |
0.81 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 43.35% |
634,864 |
0.43 |
| Q2  2025 |
| ≡ |
John Rogers - Ariel Investments |
Add 2.62% |
362,671 |
0.08 |
| ≡ |
Mason Hawkins - Southeastern Asset Management |
Add 5.58% |
381,331 |
0.38 |
| Q4  2024 |
| ≡ |
John Rogers - Ariel Investments |
Add 0.08% |
12,583 |
0.00 |
| Q4  2023 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
91,417 |
0.04 |
| Q2  2023 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 722.82% |
3,205,688 |
3.49 |
| Q1  2023 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 4.23% |
18,000 |
0.15 |
| ≡ |
Lee Ainslie - Maverick Capital |
Add 294.40% |
47,233 |
0.02 |
| Q4  2022 |
| ≡ |
Lee Ainslie - Maverick Capital |
Add 48.35% |
5,229 |
0.00 |
| Q3  2022 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
10,815 |
0.00 |
| Q2  2022 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 9.37% |
40,000 |
0.44 |
| Q1  2022 |
| ≡ |
Bill Miller - Miller Value Partners |
Add 0.56% |
22,303 |
0.02 |
| ≡ |
Samantha McLemore - Patient Capital Management |
Add 5.77% |
23,300 |
0.20 |
| Q4  2021 |
| ≡ |
Bill Miller - Miller Value Partners |
Buy |
4,017,205 |
3.06 |
| Q3  2021 |
| ≡ |
Lee Ainslie - Maverick Capital |
Add 54.76% |
1,293 |
0.00 |
| Q4  2020 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
6,754 |
0.00 |
| Q2  2020 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
304,276 |
0.06 |
| Q4  2018 |
| ≡ |
Lee Ainslie - Maverick Capital |
Buy |
202,520 |
0.03 |
| Q2  2018 |
| ≡ |
Thomas Gayner - Markel Group |
Add 106.06% |
105,000 |
0.03 |
| Q1  2018 |
| ≡ |
Thomas Gayner - Markel Group |
Buy |
99,000 |
0.02 |
| Q4  2017 |
| ≡ |
Thomas Russo - Gardner Russo & Quinn |
Buy |
6,625 |
0.00 |
| Q3  2017 |
| ≡ |
Robert Olstein - Olstein Capital Management |
Add 375.45% |
425,760 |
0.85 |
| Q2  2017 |
| ≡ |
Robert Olstein - Olstein Capital Management |
Buy |
113,400 |
0.31 |
| Q1  2016 |
| ≡ |
Thomas Russo - Gardner Russo & Quinn |
Buy |
6,625 |
0.00 |
| Q4  2015 |
| ≡ |
Thomas Gayner - Markel Group |
Add 8.90% |
52,000 |
0.04 |
| Q3  2015 |
| ≡ |
Thomas Gayner - Markel Group |
Add 18.46% |
91,000 |
0.05 |
| Q2  2015 |
| ≡ |
Thomas Gayner - Markel Group |
Add 16.82% |
71,000 |
0.05 |
| Q1  2015 |
| ≡ |
Thomas Gayner - Markel Group |
Add 26.73% |
89,000 |
0.05 |
| Q4  2014 |
| ≡ |
Thomas Gayner - Markel Group |
Add 16.43% |
47,000 |
0.04 |
| Q3  2014 |
| ≡ |
Thomas Gayner - Markel Group |
Add 13.94% |
35,000 |
0.03 |
| Q2  2014 |
| ≡ |
Thomas Gayner - Markel Group |
Add 12.56% |
28,000 |
0.03 |
| Q1  2014 |
| ≡ |
Thomas Gayner - Markel Group |
Add 20.22% |
37,500 |
0.05 |
| Q4  2013 |
| ≡ |
Thomas Gayner - Markel Group |
Add 30.18% |
43,000 |
0.06 |
| Q3  2013 |
| ≡ |
Thomas Gayner - Markel Group |
Add 1.06% |
1,500 |
0.00 |
| Q2  2013 |
| ≡ |
Thomas Gayner - Markel Group |
Add 0.71% |
1,000 |
0.00 |
| Q1  2013 |
| ≡ |
Thomas Gayner - Markel Group |
Add 38.61% |
39,000 |
0.06 |
| Q4  2012 |
| ≡ |
Thomas Gayner - Markel Group |
Add 34.67% |
26,000 |
0.04 |
| Q3  2012 |
| ≡ |
Thomas Gayner - Markel Group |
Buy |
75,000 |
0.11 |